drugset / Trial / NCT02928965
The Benefit of Minocycline on Negative Symptoms in Schizophrenia: Extent and Mechanisms
Phase 2
Completed
207 enrolled
University of Manchester
Cambridgeshire and Peterborough NHS Foundation Trust · collabCamden and Islington NHS Foundation Trust · collabCentral and North West London NHS Foundation Trust · collabGreater Manchester Mental Health NHS Foundation Trust · collabKing's College London · collabLancashire Care NHS Foundation Trust · collabManchester Mental Health & Social Care Trust · collabNHS Borders · collabNHS Fife · collabNHS Lothian · collabNorth East London Foundation Trust · collabNorthern Care Alliance NHS Foundation Trust · collabSouth London and Maudsley NHS Foundation Trust · collabUniversity College, London · collabUniversity Hospital Birmingham NHS Foundation Trust · collabUniversity of Birmingham · collabUniversity of Cambridge · collabUniversity of Edinburgh · collabWest London Mental Health NHS Trust · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to investigate if minocycline limits the development of negative symptoms in early psychosis and to test via what mechanism of action this change occurs.
Timeline
- Start
- 2013-02
- Primary completion
- 2016-05
- Completion
- 2016-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Minocycline | Small molecule | 100 mg | Oral |